EDQM Clarifies the Role of Monographs in Determining Biosimilarity
The directorate says monographs are flexible and changeable and their compliance does not on its own determine biosimilarity in biosimilars.
The European Directorate for the Quality of Medicines & Healthcare (EDQM) clarified that European Pharmacopoeia (Ph. Eur.) monographs ensure the quality of biosimilars and biotherapeutics, but compliance with monographs does not demonstrate biosimilarity. During a Feb. 8, 2017 seminar organized by the European Medicines Agency, EDQM stated that Ph. Eur. monographs, which provide tests and acceptance criteria, “are dynamic documents that can be adapted to scientific progress.”
“Ph. Eur. monographs do evolve to reflect product heterogeneity dependent on process, and this aspect is of particular relevance for manufacturing biotherapeutic products,” explained Susanne Keitel, director of the EDQM, adding that “current legislation purposely allows for monographs to be complemented with further specifications that may be needed to adequately control the quality of a given substance produced through a specific route.”
Soure: EDQM
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.
